Viking Therapeutics, Inc. (NASDAQ:VKTX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August 9, 2017, we issued a press release reporting our financial results for the second quarter and six months ended June 30, 2017 and providing a corporate update.The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 2.02 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo |
Description |
|
99.1 |
Press release issued August 9, 2017, reporting financial results for the second quarter and six months ended June 30, 2017 and providing a corporate update. |
Viking Therapeutics, Inc. ExhibitEX-99.1 2 vktx-ex991_6.htm EX-99.1 vktx-ex991_6.htm Exhibit 99.1 Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study fully enrolled,…To view the full exhibit click here
About Viking Therapeutics, Inc. (NASDAQ:VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
